news
The information below is intended for the healthcare media.
pharma& Receives EMA Approval for Pegasys® Manufacturing Site Variation, Adding Loba biotech for API Production and Securing a Stable, Long-term Supply
pharma& announces Rubraca® (rucaparib) global success and expansion Q1 2025 update
Rubraca® (rucaparib) is recommended by NICE as a first-line maintenance treatment for eligible women with BRCA-mutation negative advanced ovarian cancer
Rubraca® (rucaparib) is now reimbursed in Italy as a first-line maintenance treatment for all eligible women with advanced ovarian cancer
6/2/2025
pharma& to Highlight Long-Term Data for Rubraca® (rucaparib) in Advanced Ovarian Cancer at 2025 ESGO Annual Congress
7/11/2024
Rubraca® (rucaparib) is now reimbursed in Spain as a first-line maintenance treatment for all eligible women with advanced ovarian cancer
Rubraca® (rucaparib) is now reimbursed in France as a first-line maintenance treatment for all eligible women with advanced ovarian cancer
The pharma& Group Enters into an Exclusive Promotional Agreement with Tolmar, Inc. to Promote Rubraca® (rucaparib) in the U.S. for the Treatment of Metastatic Castration-Resistant Prostate Cancer
European Commission approves pharmaand GmbH’s Pegasys® (peginterferon alfa-2a) as a treatment for all eligible patients with the myeloproliferative neoplasms (MPNs) blood cancers polycythemia vera (PV) and essential thrombocythemia (ET)
1/7/2024
pharmaand GmbH Receives Positive CHMP Opinion for Pegasys® as a treatment for all eligible patients with polycythemia vera (PV) or essential thrombocythemia (ET)
31/5/2024
pharma& Updates on the Phase 3 ATHENA-COMBO Trial Evaluating rucaparib (Rubraca®) in Combination with nivolumab in First-line Maintenance Treatment in Women with Advanced Ovarian Cancer
30/4/2024
pharma& joins the United Nations Global Compact
pharma&’s Rubraca® (rucaparib) ATHENA-MONO Clinical Trial Data in First-Line Maintenance Treatment Suggest Benefit Continues Beyond Completion of Treatment and First Progression
1/2/2024
pharmaand GmbH’s Rubraca®▼ (rucaparib) approved in the United Kingdom as a First-Line Maintenance Treatment in Advanced Ovarian Cancer
pharmaand GmbH and GHN Pharma Nordic AB Announce Collaboration Extension and Expansion
pharma& Acquires the Global Rights to satraplatin from Dayton Therapeutics
European Commission Approves pharmaand GmbH’s Rubraca® (rucaparib) as a First-Line Maintenance Treatment in Advanced Ovarian Cancer
pharmaand GmbH Receives Positive CHMP Opinion for Rubraca® (rucaparib) as a First-Line Maintenance Treatment in Advanced Ovarian Cancer
read more in our news archive